← Back to headlines
Hims & Hers Health Stock Rises on FDA Review of Peptide Therapies
Hims & Hers Health saw its stock jump following news of the FDA's review of compounded peptide therapies, indicating market reaction to potential regulatory developments in the wellness sector.
16 Apr, 21:17 — 16 Apr, 21:17
Sources
Showing 1 of 1 sources
